TY  - JOUR
AU  - Sarink, Danja
AU  - Schock, Helena
AU  - Johnson, Theron
AU  - Overvad, Kim
AU  - Holm, Marianne
AU  - Tjønneland, Anne
AU  - Boutron-Ruault, Marie-Christine
AU  - His, Mathilde
AU  - Kvaskoff, Marina
AU  - Boeing, Heiner
AU  - Lagiou, Pagona
AU  - Papatesta, Eleni-Maria
AU  - Trichopoulou, Antonia
AU  - Palli, Domenico
AU  - Pala, Valeria
AU  - Mattiello, Amalia
AU  - Tumino, Rosario
AU  - Sacerdote, Carlotta
AU  - Bueno-de-Mesquita, H B As
AU  - van Gils, Carla H
AU  - Peeters, Petra H
AU  - Weiderpass, Elisabete
AU  - Agudo, Antonio
AU  - Sanchez-Perez, Maria-Jose
AU  - Chirlaque, Maria-Dolores
AU  - Ardanaz, Eva
AU  - Amiano, Pilar
AU  - Khaw, Kay Tee
AU  - Travis, Ruth
AU  - Dossus, Laure
AU  - Gunter, Mark
AU  - Rinaldi, Sabina
AU  - Merritt, Melissa
AU  - Riboli, Elio
AU  - Kaaks, Rudolf
AU  - Fortner, Renée T
PY  - 2017
DO  - 10.1158/1940-6207.CAPR-17-0125
UR  - http://hdl.handle.net/10668/11398
T2  - Cancer prevention research (Philadelphia, Pa.)
AB  - Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK...
LA  - en
KW  - Adult
KW  - Aged
KW  - Breast
KW  - Breast Neoplasms
KW  - Case-Control Studies
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Incidence
KW  - Middle Aged
KW  - Osteoprotegerin
KW  - Prospective Studies
KW  - RANK Ligand
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Risk Factors
TI  - Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
TY  - research article
VL  - 10
ER  -